Panmure Gordon featured in The Times

id="main" class="site-main" role="main"> }

Panmure Gordon featured in The Times

As featured in

“City trading desks are as divided as households across the country on British membership of the European Union. Simon French and David Buik, colleagues at the broker Panmure Gordon with opposing views debate the issues: Simon French asks the questions, while David Buik tries to answer them.”

Read the article here or at the Times Website

London

Panmure Gordon & Co
One New Change
(Entrance on Watling Street)
London
EC4M 9AF
UK
+44 (0)20 7886 2500

Leeds

Panmure Gordon & Co
Park House,
Park Square West
Leeds
LS1 2PW
UK
+44 (0)113 357 1150

Top

Appointment as NOMAD and sole Broker : Sphere Medical Holding plc

Sphere Medical Holding plc (AIM: SPHR.L), a medical device company, is pleased to announce the appointment of Panmure Gordon (UK) Limited as NOMAD and sole broker with immediate effect.

Appointment of Joint Broker : Gem Diamonds

Gem Diamonds Limited (GEMD.L, “Company”) is pleased to announce the appointment of Panmure Gordon (UK) Limited (“Panmure Gordon”) as Joint Broker to the Company with immediate effect.

Liberum Capital Limited and JP Morgan Cazenove will continue to act as joint brokers.

Panmure Gordon acts for Allergy Therapeutics plc in £11.5m placing

Panmure Gordon & Co, a leading independent institutional stockbroker and investment bank, is pleased to advise that it has acted as Financial adviser, Nominated Adviser and Corporate Broker on behalf of Allergy Therapeutics plc (AGY.L) in raising £11.5m.

Panmure Gordon successfully placed a total of 41,005,500 new ordinary shares at a price of 28 pence per share to raise approximately £11.5 million (before expenses) for Allergy Therapeutics plc, the fully integrated specialty pharmaceutical company specialising in allergy vaccines.

The New Shares being issued represent approximately 7.5 per cent. of the issued ordinary share capital of the Company prior to the Placing. The Placing Price represents a discount of 0.6 per cent to the average mid-market closing price over the previous 60 trading days up to and including 16 November 2015, being the last practicable day before the announcement of the Placing.

Fusionex International plc in £14m placing

Panmure Gordon & Co, a leading independent institutional stockbroker and investment bank, is pleased to advise that it has acted as placing agent and broker in the placing of 4,300,000 new ordinary shares in Fusionex International plc (“Fusionex”, “the Company” or “the Group”) raising gross proceeds of £13.975m.

The placing price was 325p per Ordinary Share and was placed at a tight discount of 1.5% to the market close.

Private M&A : Completion of sale of Kingfisher Colours Limited (“KFL”) to Sun Chemical Corporation

Private M&A : Completion of sale of KFL to  Sun Chemical Corporation

Deal team: Dugald J. Carlean/Karri Vuori/James Greenwood

Kingfisher Colours Limited, based in Reading UK, is a privately-owned cosmetics colour manufacturer serving the global cosmetics and personal care industry. The business is over 30 years old and its cosmetic pigments portfolio includes FDA certified colorants, inorganic and surface treated pigments.

Charles Stanley Securities (Now Part of Panmure Gordon & Co Ltd) were mandated by the vendors of KFL to carry out a sales process for them and presented them with a shortlist of interested parties. Sun Chemical and its parent company, DIC, have acquired Kingfisher Colours Limited for an undisclosed sum.

Panmure Gordon appointed as NOMAD & broker to Allergy Therapeutics plc (AGY.L)

Panmure Gordon & Co is pleased to announce its appointment as Nominated Adviser and broker to Allergy Therapeutics plc (“Allergy Therapeutics” or the “Company”), the fully integrated specialty pharmaceutical company.

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving revenue in the last financial year of GBP42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.

Panmure Gordon acts for GLI Finance Limited in its Acquisition of Sancus

Panmure Gordon, a leading independent institutional stockbroker and investment bank, has advised GLI Finance Limited (“GLI Finance” or “the Company”), a specialist provider of finance to small to medium sized enterprises both directly and through a variety of finance platforms, in its acquisition of Sancus Limited and Sancus (Guernsey) Limited (“SL”) for a total consideration of £37.75 million by issuing new Ordinary Shares and new redeemable zero dividend preference shares in the Company.

SL is an offshore alternative secured lending business, which makes loans to Channel Islands-based entrepreneurs, SMEs, high net worth individuals and professionals. The acquisition will provide GLI Finance with an existing loan book and an income stream from SL’s current loan book, the SL network of contacts and market presence which will provide the enlarged Group with potential access to a wide pool of capital from Channel Islands-based high net worth individuals and family offices and, it also brings additional experienced management with loan origination and underwriting capabilities to develop and drive growth in the Company’s proprietary loan book.

Panmure Gordon leads IPO for Focusrite Plc

Panmure Gordon & Co, a leading independent institutional stockbroker and investment bank, is pleased to advise that it has acted as Nominated Adviser and sole broker on the IPO of Focusrite Plc (TUNE.L) raising £22.4m.

Focusrite Plc, (“Focusrite” or the “Group”), the global music and audio products company supplying hardware and software products used by professional and amateur musicians, successfully floated on the London Stock Exchange’s AIM market following a successful placing by Panmure Gordon (UK) Limited raising £22.4 million from institutional investors.

Focusrite has multiple key strengths including a proven financial track record over the last six years, well established brands with Focusrite and Novation that bring high quality studio heritage to the wider market, a highly experienced management team built up over a number of years with a range of experience and backgrounds in the music technology industry, a diversified and international customer base across a broad geographic area and continued product innovation with its in-house development of new, technologically innovative products.

Phil Dudderidge, Executive Chairman of Focusrite, said:

“This is a momentous day for Focusrite and I’m delighted that we’ve been able to successfully complete our flotation. We look forward to rewarding both our new and existing shareholders with continued growth in revenue and profits, and increasing our market share.”

Panmure Gordon leads IPO for Midatech Pharma PLC

Panmure Gordon & Co, a leading independent institutional stockbroker and investment bank, is pleased to advise that it has acted as Nominated Adviser and sole broker on the IPO of Midatech Pharma PLC (MTPH.L) raising £32m.

Midatech Pharma PLC, (“Midatech”, the “Company” or the “Group”), the nanomedicine company developing and commercialising multiple therapeutic products to enhance the delivery of medicines in major diseases with high unmet medical needs successfully floated on the London Stock Exchange’s AIM market following a successful placing by Panmure Gordon (UK) Limited, raising GBP32 million from institutional investors including Woodford Fund Management Limited (19.99% holding after Admission), Arrowgrass Capital Partners LLP (5.3%), Legal & General Investment Management Limited (4.0%) and Octopus Investments Limited (3.6%).

Upon Admission, Midatech has completed its acquisition of Q Chip Limited and its subsidiaries (“Q Chip”), a sustained release specialist company based in Wales. Jim Phillips, CEO of Midatech Pharma plc, said: “The proceeds from the IPO will enable Midatech to rapidly move ahead, executing on the strategic plan to become a profitable, fast growth company by moving our own products forward, whilst continuing to partner our core technologies for revenue.”